Navigation Links
Mast Therapeutics Prices Public Offering Of Units
Date:6/14/2013

t Therapeutics cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on the Company's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements regarding the timing and closing of the offering, the net proceeds from the offering and their intended use and the Company's development plans for MST-188 in complications of peripheral arterial disease, including the timing of the initiation of the planned phase 2 study in acute limb ischemia.  Among the factors that could cause or contribute to material differences between the Company's actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: whether or when the offering will be completed; a shift in the allocation of the Company's resources from sickle cell disease to other indications, including acute limb ischemia, acute decompensated heart failure, blood transfusion and/or resuscitation of shock following major trauma; delays in the commencement of clinical studies, including as a result of difficulties in obtaining regulatory agency agreement on clinical development plans or clinical study design, opening trial sites, enrolling study subjects and manufacturing sufficient quantities of clinical trial material; the potential for institutional review boards or the FDA or other regulatory agencies to require additional nonclinical or clinical studies prior to initiation of the planned phase 2 clinical study of MST-188 in acute limb ischemia; and other risks and uncertainties more fully described in the Company's press releases and periodic filings with the Securities and Exchange Commission, including the Form S-1/A registration statement filed on June 14, 2013. The Company's public filings with the Securities and Exchange Commission are available at
SOURCE Mast Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Nile Therapeutics Reports 2011 Third Quarter Financial Results
3. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
4. Fate Therapeutics Strengthens Its iPSC Platform
5. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
6. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
7. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
8. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
9. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
10. Aratana Therapeutics Completes $15 Million Series B Financing
11. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... 31, 2015 , ... Ralco is honored to announce that it is the ... be held August 5-9 in Marshall. The Ralco Enrichment Center is an interactive experience ... agriculture impacts their daily lives. This unique exhibit also features a birthing center for ...
(Date:7/30/2015)... , July 30, 2015 ... by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, ... & Development, Preclinical, Clinical Trial), by End Users - ... Market is expected to reach USD 2,107.99 million by ... CAGR of 15.29%. Browse more than ...
(Date:7/30/2015)... 2015 Ascendis Pharma A/S (Nasdaq: ... innovative TransCon technology to address significant unmet medical ... six-month Phase 2 study to evaluate the safety ... 53 treatment-naïve, pre-pubertal children with growth hormone deficiency, ... with the top-line results from our Phase 2 ...
(Date:7/29/2015)... 2015 Sanofi, a global ... second quarter of 2015. CEO Olivier Brandicourt ... performance in different businesses. Watch video ... Topics covered in the interview ... - Performance drivers - Diabetes ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... Kristin Lucas, ClearTrial Senior Director of Clinical Services, will lead a ... Cash Flow and Accruals" at the CBI Forecasting & Budgeting conference. ... over clinical trial budgets and improve management of clinical trial cash ... ...
... of $0.44 -- increase of 110% from prior year , ... KNSY ), a leading medical technology company that provides ... today reported the results for its second quarter and first six ... , Record EPS of ...
... Calif., Jan. 28 NeuroFocus, the world leader in,the ... named,preeminent cognitive neuroscientist John Polich, Ph.D., as its Director ... company made this selection as it ramps up the ... the United Kingdom, France, Italy, Germany,Japan, Korea, India, and ...
Cached Biology Technology:ClearTrial Selected to Lead Industry Panel on Managing Clinical Trial Cash Flow and Accruals at CBI Conference 2ClearTrial Selected to Lead Industry Panel on Managing Clinical Trial Cash Flow and Accruals at CBI Conference 3Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 2Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 3Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 4Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 5Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 6Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 7Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 8Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 9Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 10Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 11Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 12Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 13Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 14Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 15Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 16Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 17Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 18NeuroFocus Names John Polich, World-Renowned Scientist in Brain Function and Cognition, to Head Global NeuroLab Operations 2NeuroFocus Names John Polich, World-Renowned Scientist in Brain Function and Cognition, to Head Global NeuroLab Operations 3
(Date:7/9/2015)...  Synaptics Inc. (NASDAQ: SYNA ), a leading developer ... report financial results for the fourth quarter and fiscal ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-455-2260 (conference ...
(Date:7/9/2015)... July 9, 2015  Unchained Labs just can,t ... acquisition of Avid Nano. Avid Nano designs, develops ... systems.    Also today, Unchained Labs ... easiest to use protein sizing system. The pUNk ... protein,s hydrodynamic size, size distribution, aggregation population and ...
(Date:7/8/2015)... YORK , July 8, 2015 Summary ... globally, and the fourth most fatal, with a mortality ... The poor prognosis of pancreatic cancer patients has highlighted ... treatment, which is not being met by the current ... an array of products with varying molecule types and ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... -- The Gladstone Institutes will receive funds totaling $5.6 ... major funding initiative focusing on HIV eradication. The funds ... biomedical-research organization, to explore the molecular basis for HIV ... within cells waiting for an opportunity to reemerge when ...
... testing biofilter systems as a viable alternative to releasing ... technology could reduce the overall impact of old landfills ... issue of the International Journal of Environmental Engineering ... sites generates a slow trickle of the potent greenhouse ...
... a high prevalence of vitamin D insufficiency and deficiency ... D levels was not observed in patients in southern ... Arthritis Care & Research , a journal of the ... between disease activity and vitamin D level. ...
Cached Biology News:Gladstone to receive $5.6 million in federal funds to seek a cure for AIDS 2Gladstone to receive $5.6 million in federal funds to seek a cure for AIDS 3Biofilters reduce carbon footprint of old landfill sites 2Vitamin D insufficiency prevalent among psoriatic arthritis suffers 2
... Kit, 1 kit. Convenient way ... Conjugations are carried out under mild ... Dyes are packaged in premeasured amounts ... Category: Blotting & Labeling & Detection, ...
...
Recombinant Mouse IL-23, CF...
...
Biology Products: